{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.9","upperLimit":"90.1","value":"75.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.\n\nbevacizumab\n\ncisplatin\n\nconventional surgery\n\nintensity-modulated radiation therapy","id":"OG000","title":"IMRT + Cisplatin + Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Percentage of Participants Experiencing Progression-free Survival at 2 Years","title":"Progression-free Survival at 2 Years","type":"PRIMARY","unitOfMeasure":"percentage of participants"}